Athenex, Inc. (ATNX): Price and Financial Metrics


Athenex, Inc. (ATNX): $0.18

-0.01 (-3.37%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ATNX POWR Grades

  • ATNX scores best on the Growth dimension, with a Growth rank ahead of 97.41% of US stocks.
  • ATNX's strongest trending metric is Growth; it's been moving up over the last 71 days.
  • ATNX ranks lowest in Quality; there it ranks in the 3rd percentile.

ATNX Stock Summary

  • ATNX's price/sales ratio is 0.26; that's higher than the P/S ratio of merely 7.16% of US stocks.
  • In terms of volatility of its share price, ATNX is more volatile than 93.11% of stocks we're observing.
  • ATHENEX INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 17.9%, greater than the shareholder yield of 90.82% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ATHENEX INC are SNCR, OPGN, SPOK, ACIW, and LGHL.
  • Visit ATNX's SEC page to see the company's official filings. To visit the company's web site, go to www.athenex.com.

ATNX Valuation Summary

  • ATNX's price/sales ratio is 0.3; this is 85% lower than that of the median Healthcare stock.
  • Over the past 67 months, ATNX's price/sales ratio has gone down 33.5.

Below are key valuation metrics over time for ATNX.

Stock Date P/S P/B P/E EV/EBIT
ATNX 2022-12-02 0.3 1.3 -0.2 -0.7
ATNX 2022-12-01 0.3 1.3 -0.2 -0.7
ATNX 2022-11-30 0.3 1.3 -0.2 -0.8
ATNX 2022-11-29 0.2 1.1 -0.2 -0.7
ATNX 2022-11-28 0.2 1.1 -0.2 -0.7
ATNX 2022-11-25 0.2 1.1 -0.2 -0.7

ATNX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ATNX has a Quality Grade of F, ranking ahead of 2.45% of graded US stocks.
  • ATNX's asset turnover comes in at 0.31 -- ranking 148th of 681 Pharmaceutical Products stocks.
  • XNCR, DRRX, and VRTX are the stocks whose asset turnover ratios are most correlated with ATNX.

The table below shows ATNX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.310 0.344 -0.445
2021-03-31 0.384 0.334 -0.479
2020-12-31 0.416 0.340 -0.548
2020-09-30 0.477 0.409 -0.574
2020-06-30 0.472 0.394 -0.716
2020-03-31 0.404 0.436 -0.726

ATNX Price Target

For more insight on analysts targets of ATNX, see our ATNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.17 Average Broker Recommendation 1.71 (Moderate Buy)

ATNX Stock Price Chart Interactive Chart >

Price chart for ATNX

ATNX Price/Volume Stats

Current price $0.18 52-week high $1.74
Prev. close $0.18 52-week low $0.16
Day low $0.17 Volume 762,839
Day high $0.19 Avg. volume 1,272,719
50-day MA $0.21 Dividend yield N/A
200-day MA $0.51 Market Cap 27.99M

Athenex, Inc. (ATNX) Company Bio


Athenex Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The company was founded in 2003 and is based in Buffalo, New York.


ATNX Latest News Stream


Event/Time News Detail
Loading, please wait...

ATNX Latest Social Stream


Loading social stream, please wait...

View Full ATNX Social Stream

Latest ATNX News From Around the Web

Below are the latest news stories about ATHENEX INC that investors may wish to consider to help them evaluate ATNX as an investment opportunity.

Athenex Announces Positive Results of Special Stockholder Meeting

Shareholders voted in favor of all three proposals submitted before the Special Stockholder Meeting BUFFALO, N.Y., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the results of its special meeting of stockholders (the “Special Meeting”), held as a virtual meeting on November 22, 2022. Athenex sha

Yahoo | November 22, 2022

Athenex Announces Closing of the Sale of its China API Business

BUFFALO, N.Y., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the closing of the sale of its equity interests in its China subsidiaries, which primarily represent the Company’s ownership of its active pharmaceutical ingredient (API) manufacturing business in China, to Chongqing Comfort Pharmaceut

Yahoo | November 21, 2022

Athenex Third Quarter 2022 Earnings: Beats Expectations

Athenex ( NASDAQ:ATNX ) Third Quarter 2022 Results Key Financial Results Revenue: US$33.5m (up 6.7% from 3Q 2021). Net...

Yahoo | November 9, 2022

Athenex to Participate in the 5th Annual Evercore ISI HealthCONx Conference

BUFFALO, N.Y., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will participate in the 5th Annual Evercore ISI HealthCONx Conference, taking place virtually November 29 to December 1, 2022. Dr. Johnson Lau, Chief Executive Officer of Athenex, and Dr. Dan Lang, President of Athenex Cell Th

Yahoo | November 8, 2022

Athenex, Inc. (ATNX) CEO Johnson Lau on Q3 2022 Results - Earnings Call Transcript

Athenex, Inc. (ATNX)

Q3 2022 Earnings Conference Call

November 03, 2022 08:00 AM ET

Company Participants

Tim McCarthy - MD, Investor Relations

Johnson Lau - Chief Executive Officer

Dan Lang - President, Athenex Cell Therapy

Darrel Cohen - Chief Medical Officer, Cell Therapy

Jeff Yordon - Chief Operating Officer

Joe Annoni - Chief Financial Officer

Conference Call Participants

Jon Miller - Evercore

Yale Jen - Laidlaw & Co

Presentation

Operator

Good day, ladies and gentlemen and welcome to the Athenex Third Quarter 2022 Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to Tim McCart...

SA Transcripts on Seeking Alpha | November 6, 2022

Read More 'ATNX' Stories Here

ATNX Price Returns

1-mo -9.91%
3-mo -59.09%
6-mo -64.01%
1-year -89.22%
3-year -98.99%
5-year -98.87%
YTD -86.76%
2021 -87.70%
2020 -27.57%
2019 20.33%
2018 -20.19%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.722 seconds.